Dr. Michael Lotze received his MD and PhD degrees from Northwestern University. Except for a two year period at GlaxoSmithKline, King of Prussia, PA and a dozen years on the senior staff at the National Cancer Institute in Bethesda, Maryland, Dr. Lotze has done his work at the University of Pittsburgh.
Dr. Lotze serves as associate editor of the Journal of Immunotherapy and Oncology. He initiated the first approved gene therapy protocols at the NIH and has treated over 100 patients on gene therapy protocols at the University of Pittsburgh. He is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery, and the author on over 500 scientific papers and chapters in basic and applied tumor immunology and cytokine biology.
Currently, he is the leader in the area of exploring cancer as a disorder of cell death and is devising novel strategies to approach the disease in this context.